Analysis: In U.S. health insurance market, consolidation of insurers is increasing premiums - EurekAlert!
EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC - EurekAlert!
